CenTrial Logo

Topical Bromfenac for Diabetic Macular Edema


Clinical trial finds that topical bromfenac improves effectiveness of diabetic macular edema treatment

Diabetic macular edema (DME) is a complication of diabetes that affects the eyes, specifically the macula, the central part of the retina. High blood sugar levels can damage blood vessels in the retina, causing fluid leakage and swelling. This can lead to blurred or distorted vision, making reading or seeing fine details hard. DME is a common cause of vision loss in people with diabetes. Early detection through regular eye exams is essential to prevent severe vision impairment. Treatments include anti-VEGF injections, laser therapy, or corticosteroid implants, which can help reduce swelling and preserve vision.

Clinical Trial

clinical trial investigated the safety and effectiveness of adding topical bromfenac at 0.09% in treating DME. Seventy patients with DME were included, and they were randomly divided into two groups. Both groups received monthly intravitreal ranibizumab injections for three months. The study group also received bromfenac eye drops twice daily for six months.


The patients treated with topical bromfenac alongside ranibizumab experienced significant improvements in visual acuity, more reduction in macular thickness, and less need for reinjection compared to those treated with ranibizumab alone. Topical bromfenac did not cause any side effects on the cornea.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me


The findings suggest that using topical bromfenac 0.09% twice daily can enhance and maintain the effectiveness of intravitreal ranibizumab in treating DME. It improves vision and reduces the need for additional injections, which can benefit patients with this condition. Additionally, the topical bromfenac did not result in any harmful effects on the cornea.


This research provides valuable insights into potential combination therapies for DME, offering hope for improved outcomes and better management of this sight-threatening complication of diabetes. However, further studies with larger sample sizes and extended follow-up periods are necessary to validate the findings and ensure this treatment's safety and long-term benefits. Overall, topical bromfenac shows promise as a valuable addition to the current treatment options for diabetic macular edema.

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Signup to be notified of clinical trials near you that match your condition

Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.